Melissa Robin Bowman Foster, Ali Atef Hijazi, Rebecca Opoku, Priya Varghese, Chun Li
{"title":"The Use of Hydroxyurea in the Treatment of COVID-19.","authors":"Melissa Robin Bowman Foster, Ali Atef Hijazi, Rebecca Opoku, Priya Varghese, Chun Li","doi":"10.2478/jccm-2021-0019","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The rapid worldwide spread of COVID-19 motivated medical professionals to pursue and authenticate appropriate remedies and treatment protocols. This article aims to analyze the potential benefits of one treatment protocol developed by a group of care providers caring for severe COVID-19 patients.</p><p><strong>Methods: </strong>The clinical findings of COVID-19 patients who were transferred to a specialized care hospital after unsuccessful treatment in previous institutions, were analyzed. The specialized care hospital used a treatment protocol including hydroxyurea, a medication commonly used for sickle cell treatment, to improve respiratory distress in the COVID-19 patients. None of the COVID-19 patients included in the analyzed data were diagnosed with sickle cell, and none had previously taken hydroxyurea for any other conditions.</p><p><strong>Results: </strong>In all presented cases, patients reverted to their baseline respiratory health after treatment with the hydroxyurea protocol. There was no significant difference in the correlation between COVID-19 and hydroxyurea. However, deaths were extremely low for those taking hydroxyurea.</p><p><strong>Conclusions: </strong>Fatality numbers were extremely low for those taking hydroxyurea; death could be attributed to other underlying issues.</p>","PeriodicalId":44227,"journal":{"name":"Journal of Critical Care Medicine","volume":"7 4","pages":"312-317"},"PeriodicalIF":0.9000,"publicationDate":"2021-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6e/76/jccm-07-312.PMC8647674.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Critical Care Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/jccm-2021-0019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 3
Abstract
Introduction: The rapid worldwide spread of COVID-19 motivated medical professionals to pursue and authenticate appropriate remedies and treatment protocols. This article aims to analyze the potential benefits of one treatment protocol developed by a group of care providers caring for severe COVID-19 patients.
Methods: The clinical findings of COVID-19 patients who were transferred to a specialized care hospital after unsuccessful treatment in previous institutions, were analyzed. The specialized care hospital used a treatment protocol including hydroxyurea, a medication commonly used for sickle cell treatment, to improve respiratory distress in the COVID-19 patients. None of the COVID-19 patients included in the analyzed data were diagnosed with sickle cell, and none had previously taken hydroxyurea for any other conditions.
Results: In all presented cases, patients reverted to their baseline respiratory health after treatment with the hydroxyurea protocol. There was no significant difference in the correlation between COVID-19 and hydroxyurea. However, deaths were extremely low for those taking hydroxyurea.
Conclusions: Fatality numbers were extremely low for those taking hydroxyurea; death could be attributed to other underlying issues.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
